These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 11298345)

  • 21. An in vivo analysis of cytokine production during Leishmania donovani infection in scid mice.
    Engwerda CR; Smelt SC; Kaye PM
    Exp Parasitol; 1996 Nov; 84(2):195-202. PubMed ID: 8932769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Live Attenuated Leishmania donovani Centrin Knock Out Parasites Generate Non-inferior Protective Immune Response in Aged Mice against Visceral Leishmaniasis.
    Bhattacharya P; Dey R; Dagur PK; Joshi AB; Ismail N; Gannavaram S; Debrabant A; Akue AD; KuKuruga MA; Selvapandiyan A; McCoy JP; Nakhasi HL
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004963. PubMed ID: 27580076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deficiency of p110δ isoform of the phosphoinositide 3 kinase leads to enhanced resistance to Leishmania donovani.
    Khadem F; Mou Z; Liu D; Varikuti S; Satoskar A; Uzonna JE
    PLoS Negl Trop Dis; 2014 Jun; 8(6):e2951. PubMed ID: 24945303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The resolution of lesions induced by Leishmania major in mice requires a functional Fas (APO-1, CD95) pathway of cytotoxicity.
    Conceição-Silva F; Hahne M; Schröter M; Louis J; Tschopp J
    Eur J Immunol; 1998 Jan; 28(1):237-45. PubMed ID: 9485203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolation of protective T cells from BALB/cJ mice chronically infected with Leishmania donovani.
    Holaday B; Sadick MD; Pearson RD
    J Immunol; 1988 Sep; 141(6):2132-7. PubMed ID: 3262649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology.
    Satoskar AR; Rodig S; Telford SR; Satoskar AA; Ghosh SK; von Lichtenberg F; David JR
    Eur J Immunol; 2000 Mar; 30(3):834-9. PubMed ID: 10741399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leishmania donovani phosphoproteins pp41 and pp29 re-establishes host protective immune response in visceral leishmaniasis.
    Das P; Amit A; Singh SK; Chaudhary R; Dikhit MR; Yadav A; Pandey K; Das VN; Sundram S; Das P; Bimal S
    Parasitol Int; 2015 Feb; 64(1):18-25. PubMed ID: 25224164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Critical role of IRF-5 in the development of T helper 1 responses to Leishmania donovani infection.
    Paun A; Bankoti R; Joshi T; Pitha PM; Stäger S
    PLoS Pathog; 2011 Jan; 7(1):e1001246. PubMed ID: 21253574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic glucocorticoid-induced TNF receptor-mediated amplification of CD4+ T cell responses enhances antiparasitic immunity.
    Haque A; Stanley AC; Amante FH; Rivera Fde L; Zhou Y; Kuns RD; Yardley V; Sakaguchi S; Hill GR; Engwerda CR
    J Immunol; 2010 Mar; 184(5):2583-92. PubMed ID: 20139272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma.
    Murray HW; Stern JJ; Welte K; Rubin BY; Carriero SM; Nathan CF
    J Immunol; 1987 Apr; 138(7):2290-7. PubMed ID: 3104456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune responses of Leishmania donovani infected BALB/c mice following treatment with free and vesicular sodium stibogluconate formulations.
    Banduwardene R; Mullen AB; Carter KC
    Int J Immunopharmacol; 1997 Apr; 19(4):195-203. PubMed ID: 9373770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased susceptibility of Fas ligand-deficient gld mice to Trypanosoma cruzi infection due to a Th2-biased host immune response.
    Lopes MF; Nunes MP; Henriques-Pons A; Giese N; Morse HC; Davidson WF; Araújo-Jorge TC; DosReis GA
    Eur J Immunol; 1999 Jan; 29(1):81-9. PubMed ID: 9933089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of Fas and Fas ligand on spleen T cells of experimental animals after unmodified or leukoreduced allogeneic blood transfusions.
    Hashimoto MN; Kimura EY; Yamamoto M; Bordin JO
    Transfusion; 2004 Feb; 44(2):158-63. PubMed ID: 14962305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-lymphocyte downregulation after acute viral infection is not dependent on CD95 (Fas) receptor-ligand interactions.
    Lohman BL; Razvi ES; Welsh RM
    J Virol; 1996 Nov; 70(11):8199-203. PubMed ID: 8892953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virally infected hepatocytes are resistant to perforin-dependent CTL effector mechanisms.
    Kafrouni MI; Brown GR; Thiele DL
    J Immunol; 2001 Aug; 167(3):1566-74. PubMed ID: 11466378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Local suppression of IFN-gamma in hepatic granulomas correlates with tissue-specific replication of Leishmania chagasi.
    Wilson ME; Sandor M; Blum AM; Young BM; Metwali A; Elliott D; Lynch RG; Weinstock JV
    J Immunol; 1996 Mar; 156(6):2231-9. PubMed ID: 8690913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon-γ-Producing CD4
    Romano A; Brown N; Ashwin H; Doehl JSP; Hamp J; Osman M; Dey N; Rani GF; Ferreira TR; Kaye PM
    Front Immunol; 2021; 12():700501. PubMed ID: 34557190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
    Stäger S; Smith DF; Kaye PM
    J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defects in the generation of IFN-gamma are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2-deficient mice.
    Sato N; Kuziel WA; Melby PC; Reddick RL; Kostecki V; Zhao W; Maeda N; Ahuja SK; Ahuja SS
    J Immunol; 1999 Nov; 163(10):5519-25. PubMed ID: 10553079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD95 ligand expression as a mechanism of immune escape in breast cancer.
    Müschen M; Moers C; Warskulat U; Even J; Niederacher D; Beckmann MW
    Immunology; 2000 Jan; 99(1):69-77. PubMed ID: 10651943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.